Why Clovis Oncology Fell 7.1% in August

Shares of Clovis Oncology (NASDAQ: CLVS), a commercial-stage biotech focused on cancer, fell more than 7% in August, according to data from S&P Global Market Intelligence. The decline was owed to the company sharing good and bad news with investors during in its second-quarter report.

Here's a review of the headline numbers from the company's second quarter:

Financial updates aside, Clovis also had several other highlights to share with investors:

Source: Fool.com